A model for hematopoietic death in man from irradiation of bone marrow during radioimmunotherapy
Authors:
- 11 November 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 63 (755) , 862-870
Abstract
There are numerous institutions worldwide performing clinical trials of radioimmunotherapy (RIT) for cancer. For RIT, an exponentially decaying radionuclide is attached by using a chelating agent to a specific monoclonal or polyclonal tumour antibody (e.g. antiferritin IgG). The major limitation to RIT is toxicity to normal tissue in organs other than the one containing the tumour (e.g. bone marrow). The focus of this manuscript is on modelling the risk (or probability) of hematopoietic death in man for exponentially decaying patterns of high-energy .beta. irradiation (e.g. 90Y) of bone marrow by radioimmunoglobulin injected into the blood. The analytical solutions presented are only applicable to protocols for which significant uptake of radioactivity by the bone marrow does not occur, and only for high energy .beta. emitters. However, the generic equation used to obtain the analytical solutions is applicable to any continuous pattern of high energy .beta. irradiation. A model called the "normalized dose model" was used to generate calculated values for the LD50 as a function of the effective half-time for the radioimmunoglobulin in the blood. A less complicated empirical model was used to describe the calculated values. This model is presumed to be valid for effective half-times in blood of up to about 20 days. For longer effective half-times, the LD50 can be estimated using the normalized-dose model presented. In this manuscript, we also provide a modified Weibull model that allows estimation of the risk of hematopoietic death for single or multiple injections (in one cycle) of radioimmunoglobulin, for patients with normal susceptibility to irradiation and for patients with heightened susceptibility. With the modified Weibull model, the risk of hematopoietic death depends on the level of medical treatment provided to mitigate radiation injuries.Keywords
This publication has 13 references indexed in Scilit:
- The LD50 Associated with Exposure to the Atomic Bombing of Hiroshima and NagasakiJournal of Radiation Research, 1991
- Risk Estimators for Radiation‐Induced Bone Marrow Syndrome Lethality in HumansRisk Analysis, 1988
- Predicted allowable doses to normal organs for biologically targeted radiotherapyBritish Journal of Radiology, 1988
- Limitations to the killing of tumours using radiolabelled antibodiesBritish Journal of Radiology, 1987
- Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study.Journal of Clinical Oncology, 1987
- Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.Journal of Clinical Oncology, 1985
- The LD50for uniform low LET irradiation of man; a postscriptBritish Journal of Radiology, 1985
- Clinical Studies of Radiation Effects in Man: A Preliminary Report of a Retrospective Search for Dose-Relationships in the Prodromal SyndromeRadiation Research Supplement, 1967
- An Analysis of the LD 50(30) as Related to Radiation IntensityRadiation Research, 1960
- THE ACUTE RADIATION SYNDROME IN MANAnnals of Internal Medicine, 1950